- In April 2025, PharmaJet presented new partner data at the World Vaccine Congress 2025, demonstrating that its needle-free delivery systems can boost the immune response of DNA and novel therapeutic cancer vaccines. This highlights the company's commitment to advancing vaccine effectiveness through its precision delivery technology and reinforces the potential of needle-free solutions in complex therapeutic areas
- In May 2025, CROSSJECT announced plans to launch a capital increase of approximately EUR 5 million to support the final development and production of ZEPIZURE, an emergency injectable for epilepsy crises, and to finance for other products. This strategic fundraising aims to bolster the company's financial flexibility as it targets Emergency Use Authorization (EUA) filing with the FDA for its needle-free ZENEO platform
- In March 2025, Vaxxas secured a new U.S. patent for its proprietary manufacturing technology related to its high-density microarray patch (HD-MAP) for needle-free vaccination. This patent strengthens the company's intellectual property portfolio, supporting its exclusive claim to manufacture and sell its innovative vaccination platform designed for consistent, high-speed application of dried vaccine formulations
- In May 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, announced that its Cyltezo Pen, an autoinjector option for Cyltezo (adalimumab-adbm), received approval from the U.S. Food and Drug Administration (FDA). While autoinjectors can be needle-based, this development highlights the continued focus of major pharmaceutical companies on self-administered and user-friendly drug delivery devices, including those with needle-free or minimized-needle designs, aligning with broader market trends
- In February 2025, Micron Biomedical secured over USD 33 million in funding, including a grant from the Coalition for Epidemic Preparedness Innovations (CEPI), to advance its dissolvable microarray technology for needle-free vaccines. This funding supports the development of a next-generation vaccine platform that aims to overcome cold chain challenges and reduce sharps waste, underscoring the potential for innovative needle-free delivery in global health initiatives
